SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.
SynZeal will update these details as per new development or finding in product specification without further noticed.
Chemical Name: Ethyl 2-((2-(4-((4-fluorobenzyl)carbamoyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)propan-2-yl)amino)-2-oxoacetate
Shipping Temperature: Ambient
HSN Code: 38229010
Country of Origin: India
Smiles: O=C(OCC)C(NC(C)(C1=NC(C(NCC2=CC=C(F)C=C2)=O)=C(O)C(N1C)=O)C)=O
Raltegravir Diketo Ethoxy Impurity is chemically Ethyl 2-((2-(4-((4-fluorobenzyl)carbamoyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)propan-2-yl)amino)-2-oxoacetate. Raltegravir Diketo Ethoxy Impurity is supplied with detailed characterization data compliant with regulatory guideline. Raltegravir Diketo Ethoxy Impurity can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Raltegravir.
The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.
Development and validation of stability indicating RP-HPLC assay method of raltegravir in tablet dosage forms
By Shirisha, V.; Sairaju, B.; Illendula, Santhosh; Dutt, K. Rajeswar
From World Journal of Pharmacy and Pharmaceutical Sciences (2019), 8(10), 668-692
Stability indicating reverse-phase high performance liquid chromatography method for the determination of raltegravir in bulk and pharmaceutical formulation
By Annapurna, Mukthinuthalapati Mathrusri; Teja, Gunnam Ravi; Hemchand, S.; Babu, R. Ravi Chandra
From International Journal of Green Pharmacy (2018), 12(1Suppl.), S177-S180
Development and validation of RP-HPLC method for determination of raltegravir and its impurities in bulk drug and dosage forms
By Balaji, M.; AppaRao, K. M. Ch.; Ramakrishna, K.; Srinivasarao, V.
From Pharma Science Monitor (2014), 5(3Suppl.1), 187-196, 10 pp.